Skip to main content

Table 5 Predictors of pneumonia in RA patients by the Cox-hazard model (univariate analysis)

From: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

 

Hazard ratio

P value

95% CI

Demographics

 Age (years)

1.058

0.002

1.021–1.095

 Gender, male

1.073

0.870

0.464–2.480

Laboratory data

 CRP (mg/dl)

1.321

<0.0001

1.140–1.531

 Serum albumin (g/dl)

0.414

0.051

0.171–1.004

 Serum creatinine (mg/dl)

1.358

0.413

0.652–2.828

RA characteristics

 RA duration (years)

1.002

0.927

0.968–1.036

 HAQ

1.219

0.366

0.794–1.871

 DAS28 (CRP)

0.894

0.498

0.646–1.237

 SDAI

0.970

0.281

0.919–1.025

 CDAI

0.949

0.115

0.890–1.013

Comorbidity

 Smoking history

0.936

0.877

0.405–2.165

 Cardiovascular disease

1.745

0.122

0.862–3.533

 Metabolic disease

1.612

0.211

0.763–3.405

 CKD

1.814

0.415

0.433–7.592

 Autoimmune disease

0.723

0.750

0.099–5.299

 Interstitial pneumonia

4.449

<0.0001

2.143–9.237

PPSV23 vaccination

1.048

0.894

0.523–2.099

Treatment

 PSL

1.314

0.443

0.654–2.643

 Dose of prednisolone (mg/day)

1.117

0.102

0.978–1.276

 MTX

0.778

0.493

0.381–1.593

 Dose of MTX (mg/week)

0.962

0.634

0.821–1.128

 TAC

0.956

0.934

0.335–2.727

 Biologics

0.544

0.088

0.270–1.094

  1. PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein, RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, CKD chronic kidney disease, PSL prednisolone, MTX methotrexate, TAC tacrolimus, CI confidence interval